Ponto J - Search Results

1

Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.

Bushnell D, Menda Y, O'Dorisio T, Madsen M, Miller S, Carlisle T, Squires S, Kahn D, Walkner W, Connolly M, O'Dorisio S, Karwal M, Ponto J, Bouterfa H. Bushnell D, et al. Among authors: ponto j. Cancer Biother Radiopharm. 2004 Feb;19(1):35-41. doi: 10.1089/108497804773391658. Cancer Biother Radiopharm. 2004. PMID: 15068609 Clinical Trial.

2

Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher(TM)) in patients with diffuse somatostatin receptor positive liver metastases.

Bushnell D, Menda Y, Madsen M, O'Dorisio T, Carlisle T, Zehr P, Ponto L, Karwal M, Parker S, Ponto J, Connolly M, Bouterfa H. Bushnell D, et al. Among authors: ponto j, ponto l. Cancer Biother Radiopharm. 2003 Aug;18(4):581-8. doi: 10.1089/108497803322287664. Cancer Biother Radiopharm. 2003. PMID: 14503953 Clinical Trial.

3

Diuretic-enhanced I-131 clearance after ablation therapy for differentiated thyroid cancer.

Seabold JE, Ben-Haim S, Pettit WA, Gurli NJ, Rojeski MT, Flanigan MJ, Ponto JA, Bricker JA. Seabold JE, et al. Among authors: ponto ja. Radiology. 1993 Jun;187(3):839-42. doi: 10.1148/radiology.187.3.8497641. Radiology. 1993. PMID: 8497641

4

The syringe shield rule: model for practitioner-initiated regulatory reform.

Ponto JA. Ponto JA. J Am Pharm Assoc (Wash). 2002 Nov-Dec;42(6):871-4. doi: 10.1331/108658002762063727. J Am Pharm Assoc (Wash). 2002. PMID: 12482012

5

Dosimetry of [15O]water: a physiologic approach.

Narayana S, Hichwa RD, Boles Ponto LL, Ponto JA, Watkins GL. Narayana S, et al. Among authors: ponto ja. Med Phys. 1996 Jan;23(1):159-68. doi: 10.1118/1.597793. Med Phys. 1996. PMID: 8700028

6

Dispensing and administration of radiopharmaceuticals for dacryoscintigraphy.

Ponto JA. Ponto JA. J Am Pharm Assoc (2003). 2006 Nov-Dec;46(6):749-50. doi: 10.1331/1544-3191.46.6.749.ponto. J Am Pharm Assoc (2003). 2006. PMID: 17176691 No abstract available.

7

Uses and limitations of positron emission tomography in clinical pharmacokinetics/dynamics (Part I).

Ponto LL, Ponto JA. Ponto LL, et al. Among authors: ponto ja. Clin Pharmacokinet. 1992 Mar;22(3):211-22. doi: 10.2165/00003088-199222030-00003. Clin Pharmacokinet. 1992. PMID: 1559312 Review.

8

Uses and limitations of positron emission tomography in clinical pharmacokinetics/dynamics (Part II).

Ponto LL, Ponto JA. Ponto LL, et al. Among authors: ponto ja. Clin Pharmacokinet. 1992 Apr;22(4):274-83. doi: 10.2165/00003088-199222040-00003. Clin Pharmacokinet. 1992. PMID: 1606787 Review.

9

Cost-effectiveness of routine radiochemical quality assurance testing of technetium Tc 99m radiopharmaceuticals.

Ponto JA, Ponto LL. Ponto JA, et al. Among authors: ponto ll. Am J Hosp Pharm. 1986 May;43(5):1218-22. Am J Hosp Pharm. 1986. PMID: 3087163

10

Prescribed doses requiring metric volume measurements.

Ponto JA, Ponto LL. Ponto JA, et al. Among authors: ponto ll. Am Pharm. 1986 Apr;NS26(4):5. Am Pharm. 1986. PMID: 3706130 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

94 results

Search Page

Filters